IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact
S Bird, C Pawlyn - Blood, The Journal of the American Society …, 2023 - ashpublications.org
Immunomodulatory agents (IMiDs) are a cornerstone of treatment for patients with multiple
myeloma. IMiDs are used in therapeutic combinations at all stages of disease and are …
myeloma. IMiDs are used in therapeutic combinations at all stages of disease and are …
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Emergence of drug resistance to all available therapies is the major challenge to improving
survival in myeloma. Cereblon (CRBN) is the essential binding protein of the widely used …
survival in myeloma. Cereblon (CRBN) is the essential binding protein of the widely used …
Pharmacodynamic changes in tumor and immune cells drive Iberdomide's clinical mechanisms of activity in relapsed and refractory Multiple Myeloma
M Amatangelo, E Flynt, N Stong, P Ray… - Cell Reports …, 2024 - cell.com
Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical
development in multiple myeloma (MM). The analysis of biomarker samples from …
development in multiple myeloma (MM). The analysis of biomarker samples from …
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
PA Huang, SL Beedie, CH Chau, DJ Venzon, S Gere… - Scientific reports, 2019 - nature.com
Abstract Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising
results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the …
results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the …
[PDF][PDF] Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma
S Bird - 2023 - repository.icr.ac.uk
Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma treatment and
newer cereblon E3 ligase modulating drugs (CELMoDs) are in clinical trials. However, a …
newer cereblon E3 ligase modulating drugs (CELMoDs) are in clinical trials. However, a …